TN2014000526A1 - Injectable supersaturated acetaminophen solution for spinal administration - Google Patents

Injectable supersaturated acetaminophen solution for spinal administration

Info

Publication number
TN2014000526A1
TN2014000526A1 TN2014000526A TN2014000526A TN2014000526A1 TN 2014000526 A1 TN2014000526 A1 TN 2014000526A1 TN 2014000526 A TN2014000526 A TN 2014000526A TN 2014000526 A TN2014000526 A TN 2014000526A TN 2014000526 A1 TN2014000526 A1 TN 2014000526A1
Authority
TN
Tunisia
Prior art keywords
spinal administration
acetaminophen solution
injectable
solution
supersaturated acetaminophen
Prior art date
Application number
TN2014000526A
Other languages
English (en)
Inventor
Augusto Mitidieri
Elisabetta Donati
Nicola Caronzolo
Original Assignee
Sint Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000526(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sint Sa filed Critical Sint Sa
Publication of TN2014000526A1 publication Critical patent/TN2014000526A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2014000526A 2012-06-29 2014-12-18 Injectable supersaturated acetaminophen solution for spinal administration TN2014000526A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale
PCT/IB2013/055277 WO2014002042A1 (fr) 2012-06-29 2013-06-27 Solution d'acétaminophène injectable sursaturée pour l'administration spinale

Publications (1)

Publication Number Publication Date
TN2014000526A1 true TN2014000526A1 (en) 2016-03-30

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2014000526A TN2014000526A1 (en) 2012-06-29 2014-12-18 Injectable supersaturated acetaminophen solution for spinal administration

Country Status (44)

Country Link
US (2) US11344517B2 (fr)
EP (1) EP2874602B1 (fr)
JP (1) JP5876620B2 (fr)
KR (1) KR102118227B1 (fr)
CN (1) CN104487051B (fr)
AP (1) AP2014008152A0 (fr)
AR (1) AR091633A1 (fr)
AU (1) AU2013282753B2 (fr)
BR (1) BR112014032818B1 (fr)
CA (1) CA2876801C (fr)
CL (1) CL2014003536A1 (fr)
CO (1) CO7240357A2 (fr)
CR (1) CR20150036A (fr)
CU (1) CU20140150A7 (fr)
CY (1) CY1117691T1 (fr)
DK (1) DK2874602T3 (fr)
DO (1) DOP2014000302A (fr)
EA (1) EA028909B1 (fr)
EC (1) ECSP15000500A (fr)
ES (1) ES2578012T3 (fr)
GE (1) GEP201706689B (fr)
HR (1) HRP20160706T1 (fr)
HU (1) HUE029431T2 (fr)
IL (1) IL236423A (fr)
IT (1) ITMI20121154A1 (fr)
MA (1) MA37811B1 (fr)
MD (1) MD4537C1 (fr)
ME (1) ME02431B (fr)
MX (1) MX369264B (fr)
MY (1) MY169251A (fr)
NI (1) NI201400147A (fr)
NZ (1) NZ703829A (fr)
PE (1) PE20150331A1 (fr)
PH (1) PH12015500178A1 (fr)
PL (1) PL2874602T3 (fr)
PT (1) PT2874602T (fr)
RS (1) RS54844B1 (fr)
SG (2) SG10201704482YA (fr)
SI (1) SI2874602T1 (fr)
SM (1) SMT201600248B (fr)
TN (1) TN2014000526A1 (fr)
UA (1) UA117101C2 (fr)
WO (1) WO2014002042A1 (fr)
ZA (1) ZA201409478B (fr)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646400B1 (fr) * 1993-04-14 2001-07-18 Nippon Sanso Corporation Appareil reducteur d'oxygene dissous
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
SK2822004A3 (sk) * 2001-12-18 2005-01-03 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Parenterálny prípravok obsahujúci paracetamol
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
US9943479B2 (en) * 2006-07-18 2018-04-17 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
US9399012B2 (en) * 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
WO2009098716A2 (fr) 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Compositions pharmaceutiques aqueuses stables
WO2009143558A1 (fr) 2008-05-26 2009-12-03 Silphion Pty Limited Formulations injectables
EP2243477A1 (fr) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracétamol destiné à l'administration parentérale
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
CA2802303C (fr) * 2010-06-30 2016-06-14 Troikaa Pharmaceuticals Limited Compositions pharmaceutiques contenant du paracetamol et procede pour les preparer

Also Published As

Publication number Publication date
MA37811A1 (fr) 2016-10-31
KR102118227B1 (ko) 2020-06-03
ECSP15000500A (es) 2015-11-30
MX2014015402A (es) 2015-06-17
EA028909B1 (ru) 2018-01-31
CR20150036A (es) 2015-03-13
CN104487051B (zh) 2017-12-12
MA37811B1 (fr) 2017-07-31
MD4537C1 (ro) 2018-07-31
IL236423A (en) 2017-07-31
PE20150331A1 (es) 2015-03-07
PT2874602T (pt) 2016-07-13
CA2876801C (fr) 2020-11-03
CU20140150A7 (es) 2015-10-27
US20150148379A1 (en) 2015-05-28
RS54844B1 (sr) 2016-10-31
BR112014032818A2 (pt) 2017-06-27
JP2015522004A (ja) 2015-08-03
PH12015500178B1 (en) 2015-04-06
MD4537B1 (ro) 2017-12-31
GEP201706689B (en) 2017-06-26
UA117101C2 (uk) 2018-06-25
BR112014032818B1 (pt) 2022-06-14
AU2013282753B2 (en) 2017-03-02
ME02431B (fr) 2016-09-20
ES2578012T3 (es) 2016-07-20
JP5876620B2 (ja) 2016-03-02
EP2874602B1 (fr) 2016-03-30
AR091633A1 (es) 2015-02-18
HRP20160706T1 (hr) 2016-08-12
PL2874602T3 (pl) 2016-10-31
US20160128955A1 (en) 2016-05-12
MY169251A (en) 2019-03-19
DOP2014000302A (es) 2015-03-15
ZA201409478B (en) 2016-01-27
CA2876801A1 (fr) 2014-01-03
CL2014003536A1 (es) 2015-05-08
ITMI20121154A1 (it) 2013-12-30
SMT201600248B (it) 2016-08-31
EP2874602A1 (fr) 2015-05-27
DK2874602T3 (en) 2016-07-04
NI201400147A (es) 2015-04-13
CY1117691T1 (el) 2017-05-17
CN104487051A (zh) 2015-04-01
US11344517B2 (en) 2022-05-31
IL236423A0 (en) 2015-02-26
PH12015500178A1 (en) 2015-04-06
EA201500065A1 (ru) 2015-10-30
HUE029431T2 (en) 2017-03-28
MD20140138A2 (ro) 2015-06-30
AU2013282753A1 (en) 2015-02-05
KR20150027160A (ko) 2015-03-11
SG11201408479WA (en) 2015-01-29
NZ703829A (en) 2016-06-24
SI2874602T1 (sl) 2016-09-30
AP2014008152A0 (en) 2014-12-31
WO2014002042A1 (fr) 2014-01-03
CO7240357A2 (es) 2015-04-17
SG10201704482YA (en) 2017-07-28
MX369264B (es) 2019-11-04

Similar Documents

Publication Publication Date Title
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
IN2014DN09434A (fr)
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
BR112015026325A2 (pt) dosagem oral de compostos glp-1
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
MX2014010928A (es) Compuestos de heterociclilo como inhibidores de mek.
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015013091A (es) Metodos mejorados de uso para secretoglobinas humanas recombinantes.
WO2014071168A3 (fr) Administration d'inhibiteurs de la signalisation tgfbêta, dérivés de benzothiazépine ou combinaisons de ceux-ci pour améliorer la fonction musculaire chez des patients cancéreux
PH12015500178A1 (en) Injectable supersaturated acetaminophen solution for spinal administration
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
TN2016000064A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
MD4291C1 (ro) Preparat medicamentos pentru tratamentul otitelor